Biogen buys Nightstar in search of more eye gene therapies

Shelling out roughly $800 million, the big biotech will get its hands on two mid- to late-stage treatments that it claims could launch in the next few years.

By Jacob Bell • March 4, 2019

Bristol-Myers hits a bump on road to Celgene takeover

Wellington Management, the largest institutional holder of Bristol-Myers, said it doesn't support the mega-deal, a position that could unnerve other investors.

By Jacob Bell • Feb. 28, 2019

Novartis moves forward on CV drug, paying $150M to Ionis, Akcea

The Swiss pharma will now take the lead on a Phase 3 cardiovascular outcomes study after mulling over Phase 2 data from November.

By Andrew Dunn • Feb. 26, 2019

Pharmacquired: What would a Clovis takeout look like?

Wall Street analysts suspect a potential suitor would be a large pharma with a presence in oncology but no access to a PARP inhibitor.

By Jacob Bell • Feb. 26, 2019

GE selling off biopharma business in $21.4B deal

Danaher's massive buy bolsters its life sciences unit. GE, meanwhile, plans to strengthen its balance sheet with the cash infusion and is reportedly pausing IPO plans for GE Healthcare.

By Andrew Dunn • Feb. 25, 2019

Roche acquires Spark in $4.8B gene therapy play

It's the latest evidence of pharma's growing appetite to expand in a field where Spark has been a leader with development of its approved treatment Luxturna.

By Jacob Bell • Feb. 25, 2019

AbbVie returns to Voyager, searching for Parkinson's gene therapy

The R&D deal puts more than $1 billion on the table in milestone payments, as the companies hunt for a one-time treatment for Parkinson's disease.

By Andrew Dunn • Feb. 22, 2019

J&J invests in integrin therapies via Morphic deal

Biotech Morphic has landed another big pharma partner just a few months after reaching a development deal with AbbVie.

By Andrew Dunn • Feb. 21, 2019

Merck takes a shot on Immune Design

The big pharma put up around $300 million to acquire the immunotherapy company and strengthen its cancer vaccine capabilities.

By Jacob Bell • Feb. 21, 2019

As Lilly deal closes, Bayer secures full rights to Loxo's Vitrakvi

With the targeted cancer drug now exclusively held by Bayer, Lilly's buyout of Loxo becomes an $8 billion bet on the promise of the biotech's RET inhibitor.

By Ned Pagliarulo • Feb. 15, 2019

Charles River Labs snaps up early-stage CRO for $510M

Acquiring Citoxlab will build out the contract research organization's footprint into Eastern Europe.

By Suzanne Elvidge • Feb. 14, 2019

Jazz set to lose rights to Erwinaze after partner cancels deal

While the lost rights would be a hit to Jazz's revenues, the company has a recombinant version of drug that analysts believe could cushion the blow. 

By Kristin Jensen • Feb. 13, 2019

Lilly lowers 2019 revenue hopes, citing Lartruvo failure

Lartruvo's clinical failure, pricing pressure and an $8 billion acquisition have caused Lilly to shift business expectations for 2019.

By Andrew Dunn • Feb. 6, 2019

Xencor inks $120M deal with Roche for preclinical bispecific

The deal puts a notably high valuation on Xencor's preclinical candidate — reflective of Roche's apparent interest in expanding its bispecifics pipeline.

By Suzanne Elvidge • Feb. 6, 2019

GSK bets billions more on oncology

The U.K. drugmaker put nearly 4 billion euros on the table to jointly develop and commercialize one of Merck KGaA's investigational immunotherapies.

By Jacob Bell • Feb. 5, 2019

'Strategic fit' with Bristol-Myers kept Celgene from casting wider net in deal negotiations

Celgene reached out to only one other company about a potential deal during negotiations with Bristol-Myers over what became a $74 billion buyout.

By Ned Pagliarulo • Feb. 1, 2019

J&J inks deal with MeiraGTx for retinal disease gene therapies

The early-stage deal is a sign of growing interest from pharma in advancing gene therapy development, analysts said.

By Suzanne Elvidge • Feb. 1, 2019

Voyager vaults higher on Neurocrine deal for Parkinson's gene therapy

Shares in Voyager rose by 40% after news Neurocrine will pay $165 million upfront in a collaboration centered on two experimental gene therapies.

By Andrew Dunn • Jan. 29, 2019

Amid controversies, J&J voted most admired pharma

The big pharma has come under fire in recent months for misrepresenting hip implant products and, to a much larger extent, its talc powder business.​

By Jacob Bell • Jan. 23, 2019

A flashy 2019 start to pharma M&A, but will it last?

Recent high-profile acquisitions don't fully clear up what the buyer's market will look like in an expected bumper year for dealmaking.

By Jacob Bell • Jan. 22, 2019

7 biopharma trends to watch in 2019

Intensifying political pressure, surging cancer drug investment and the rise of pharma chief digital officers are among the factors which look set to shape the industry's next 12 months.

By Ned Pagliarulo • Jan. 17, 2019

Lilly rushed its Loxo deal to have a big reveal at JPM

While Lilly's buy sent ripples through the biotech landscape, new information shows the pharma was the only company to bid on the cancer specialist.

By Jacob Bell • Jan. 17, 2019

Shire deal done, Takeda turns to task of forging top pharma

"Shire accelerates us by five years," Andy Plump, head of R&D at Takeda, said in an interview detailing the impact of the now complete $62 billion deal. 

By Ned Pagliarulo • Jan. 9, 2019

AbbVie takes $4B impairment charge on Stemcentrx

The pharma's $5.6 billion purchase in 2016 has soured with clinical setbacks on a leading asset, resulting in a multi-billion write-down.

By Suzanne Elvidge • Jan. 7, 2019

Lilly to buy Loxo Oncology for $8B

On the heels of the Bristol-Celgene mega-deal, Lilly will dive deeper into genetic-based cancer therapies with its buy of the Connecticut-based startup.

By Andrew Dunn • Jan. 7, 2019